PH12012500826A1 - Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists - Google Patents

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Info

Publication number: PH12012500826A1
Authority: PH; Philippines
Prior art keywords: antagonists; variable domains; tnfr1; stable anti; antibody variable
Prior art date: 2009-10-27

Application number

PH1/2012/500826A

Other languages

English (en)

Inventor

Silva Inusha De

Armin Sepp

Adriaan Allart Stoop

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-27

Filing date

2010-10-25

Publication date

2013-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012500826(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2013-01-07 Publication of PH12012500826A1 publication Critical patent/PH12012500826A1/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PH1/2012/500826A 2009-10-27 2010-10-25 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists PH12012500826A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25523509P	2009-10-27	2009-10-27
PCT/EP2010/066046 WO2011051217A1 (fr)	2009-10-27	2010-10-25	Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Publications (1)

Publication Number	Publication Date
PH12012500826A1 true PH12012500826A1 (en)	2013-01-07

Family

ID=43382391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH1/2012/500826A PH12012500826A1 (en)	2009-10-27	2010-10-25	Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Country Status (27)

Country	Link
US (1)	US20150210767A1 (fr)
EP (1)	EP2493504B1 (fr)
JP (1)	JP2013507978A (fr)
KR (1)	KR20120101417A (fr)
CN (1)	CN102686239B (fr)
AR (1)	AR078763A1 (fr)
AU (1)	AU2010311640B2 (fr)
BR (1)	BR112012010114A2 (fr)
CA (1)	CA2777312A1 (fr)
CL (1)	CL2012001055A1 (fr)
CO (1)	CO6612254A2 (fr)
CR (1)	CR20120197A (fr)
DO (1)	DOP2012000113A (fr)
EA (1)	EA022898B1 (fr)
ES (1)	ES2552177T3 (fr)
IL (1)	IL218860A0 (fr)
MA (1)	MA33758B1 (fr)
MX (1)	MX2012005024A (fr)
NZ (1)	NZ599114A (fr)
PE (1)	PE20121564A1 (fr)
PH (1)	PH12012500826A1 (fr)
SG (1)	SG10201500274TA (fr)
TW (1)	TW201125877A (fr)
UA (1)	UA107200C2 (fr)
UY (1)	UY32969A (fr)
WO (1)	WO2011051217A1 (fr)
ZA (1)	ZA201203052B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA022925B1 (ru) *	2009-02-19	2016-03-31	Глаксо Груп Лимитед	Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
WO2012172070A1 (fr) *	2011-06-17	2012-12-20	Glaxo Group Limited	Antagonistes du récepteur 1 du facteur de nécrose tumorale
EP2951192A1 (fr) *	2013-01-31	2015-12-09	Glaxo Group Limited	Procédé de production de protéine
WO2015104322A1 (fr)	2014-01-09	2015-07-16	Glaxosmithkline Intellectual Property Development Limited	Traitement de maladies inflammatoires avec des antagonistes anti-tnfr1 non compétitifs
US10689452B2 (en) *	2016-04-05	2020-06-23	Universität Stuttgart	Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof
US12472266B2 (en)	2019-02-21	2025-11-18	Enosi Therapeutics Corporation	Antibodies and enonomers
JP2023541816A (ja)	2020-08-27	2023-10-04	イノージ・セラピューティクス・コーポレイション	自己免疫性疾患および癌を治療するための方法および組成物
WO2022117569A1 (fr)	2020-12-02	2022-06-09	Oncurious Nv	Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
CN114699533B (zh) *	2022-05-06	2023-05-09	郑州大学	一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用
WO2025049818A1 (fr)	2023-08-29	2025-03-06	Enosi Therapeutics Corporation	Antagonistes tnfr1 dépourvus d'activité agoniste et leurs utilisations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0307434B2 (fr)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Anticorps alteres
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
JP3095168B2 (ja)	1988-02-05	2000-10-03	エル．モリソン，シェリー	ドメイン‐変性不変部を有する抗体
EP0768377A1 (fr)	1988-09-02	1997-04-16	Protein Engineering Corporation	Production et sélection de protéines de liaison diversifiées de recombinaison
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
WO1994026087A2 (fr)	1993-05-14	1994-11-24	Connor Kim C O	Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
ES2283936T3 (es)	1997-07-07	2007-11-01	Medical Research Council	Procedimiento de clasificacion in vitro.
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
EP1263788A2 (fr)	2000-02-11	2002-12-11	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
WO2003076567A2 (fr)	2002-03-05	2003-09-18	Eli Lilly And Company	Proteines hybrides g-csf heterologues
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (fr)	2002-06-28	2005-12-07	Domantis Limited	Ligand
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP2284192A3 (fr)	2002-11-08	2011-07-20	Ablynx N.V.	Anticorps de Camelidae pour administration sublinguale
JP2006523090A (ja)	2002-12-27	2006-10-12	ドマンティスリミテッド	リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
US20090005257A1 (en)	2003-05-14	2009-01-01	Jespers Laurent S	Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
SI1639011T1 (sl)	2003-06-30	2009-04-30	Domantis Ltd	Pegilirana protitelesa z enojno domeno (dAb)
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
CN101084014A (zh) *	2004-10-08	2007-12-05	杜门蒂斯有限公司	抗肿瘤坏死因子受体1的单域抗体及其使用方法
EP1841452B8 (fr) *	2004-10-08	2014-06-11	Domantis Limited	Anticorps a domaine unique contre le tnfr1 et procedes et leur utilisations
GB0521621D0 (en)	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
GB0724331D0 (en) *	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
AU2008259590A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Methods for selecting protease resistant polypeptides
EA022925B1 (ru) *	2009-02-19	2016-03-31	Глаксо Груп Лимитед	Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
ES2655071T3 (es) *	2009-02-19	2018-02-16	Glaxo Group Limited	Variantes de unión de anti-albúmina de suero mejoradas

2010
- 2010-10-25 TW TW099136369A patent/TW201125877A/zh unknown
- 2010-10-25 CN CN201080059618.5A patent/CN102686239B/zh not_active Expired - Fee Related
- 2010-10-25 PH PH1/2012/500826A patent/PH12012500826A1/en unknown
- 2010-10-25 ES ES10774177.9T patent/ES2552177T3/es active Active
- 2010-10-25 CA CA2777312A patent/CA2777312A1/fr not_active Abandoned
- 2010-10-25 UA UAA201204796A patent/UA107200C2/uk unknown
- 2010-10-25 MX MX2012005024A patent/MX2012005024A/es not_active Application Discontinuation
- 2010-10-25 NZ NZ599114A patent/NZ599114A/en not_active IP Right Cessation
- 2010-10-25 JP JP2012535767A patent/JP2013507978A/ja active Pending
- 2010-10-25 UY UY0001032969A patent/UY32969A/es not_active Application Discontinuation
- 2010-10-25 EA EA201290172A patent/EA022898B1/ru not_active IP Right Cessation
- 2010-10-25 EP EP10774177.9A patent/EP2493504B1/fr active Active
- 2010-10-25 BR BR112012010114A patent/BR112012010114A2/pt not_active IP Right Cessation
- 2010-10-25 AU AU2010311640A patent/AU2010311640B2/en not_active Ceased
- 2010-10-25 PE PE2012000560A patent/PE20121564A1/es not_active Application Discontinuation
- 2010-10-25 AR ARP100103911A patent/AR078763A1/es unknown
- 2010-10-25 KR KR1020127013723A patent/KR20120101417A/ko not_active Withdrawn
- 2010-10-25 SG SG10201500274TA patent/SG10201500274TA/en unknown
- 2010-10-25 WO PCT/EP2010/066046 patent/WO2011051217A1/fr not_active Ceased
2012
- 2012-03-27 IL IL218860A patent/IL218860A0/en unknown
- 2012-03-29 CO CO12053463A patent/CO6612254A2/es unknown
- 2012-04-18 DO DO2012000113A patent/DOP2012000113A/es unknown
- 2012-04-23 CR CR20120197A patent/CR20120197A/es unknown
- 2012-04-25 ZA ZA2012/03052A patent/ZA201203052B/en unknown
- 2012-04-25 CL CL2012001055A patent/CL2012001055A1/es unknown
- 2012-05-18 MA MA34878A patent/MA33758B1/fr unknown
2015
- 2015-04-09 US US14/682,176 patent/US20150210767A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20120101417A (ko)	2012-09-13
BR112012010114A2 (pt)	2017-08-08
CA2777312A1 (fr)	2011-05-05
MX2012005024A (es)	2012-09-07
NZ599114A (en)	2014-09-26
ES2552177T3 (es)	2015-11-26
TW201125877A (en)	2011-08-01
UA107200C2 (uk)	2014-12-10
DOP2012000113A (es)	2012-08-15
EP2493504B1 (fr)	2015-10-07
PE20121564A1 (es)	2012-11-29
CN102686239A (zh)	2012-09-19
AU2010311640A1 (en)	2012-05-10
AR078763A1 (es)	2011-11-30
MA33758B1 (fr)	2012-11-01
SG10201500274TA (en)	2015-03-30
JP2013507978A (ja)	2013-03-07
CL2012001055A1 (es)	2012-10-05
US20150210767A1 (en)	2015-07-30
IL218860A0 (en)	2012-06-28
WO2011051217A1 (fr)	2011-05-05
EA201290172A1 (ru)	2013-04-30
EP2493504A1 (fr)	2012-09-05
EA022898B1 (ru)	2016-03-31
CO6612254A2 (es)	2013-02-01
CN102686239B (zh)	2016-02-03
UY32969A (es)	2011-05-31
CR20120197A (es)	2012-06-22
AU2010311640B2 (en)	2015-01-29
ZA201203052B (en)	2013-09-25

Publication	Publication Date	Title
MX2011008799A (es)	2011-09-27	Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
MX2009013211A (es)	2010-04-09	Polipeptidos, dominios variables de anticuerpos y antagonistas.
MX2009012968A (es)	2010-04-01	Polipeptidos, dominios variables de anticuerpo y antagonistas.
WO2008149146A3 (fr)	2009-06-11	Polypeptides, domaines variables d'anticorps et antagonistes
EA201000785A1 (ru)	2011-02-28	Композиции для доставки в легкие
EA201290172A1 (ru)	2013-04-30	Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1
PH12013502192A1 (en)	2015-10-12	Antibodies against human angiopoietin 2
MY153198A (en)	2015-01-29	Inhibitors of protein aggregation
MX2012007806A (es)	2012-08-01	Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PH12018500641A1 (en)	2019-07-29	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TW201129381A (en)	2011-09-01	Antibodies against human CSF-1R and uses thereof
MX336682B (es)	2016-01-27	Anticuerpos contra csf-1r humanos y usos de los mismos.
EP2576578A4 (fr)	2013-12-04	Formes polymorphiques du 2'-o-fucosyllactose et leurs procédés de production
MX2009010977A (es)	2010-02-12	Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
EP3450459A3 (fr)	2019-04-24	Anticorps anti-cdh3 et leurs utilisations
NZ603191A (en)	2015-02-27	Methods for the treatment of il-1b related conditions
MX2009009816A (es)	2009-11-23	Anticuerpos monoclonales para el tratamiento del cancer.
MX337358B (es)	2016-02-29	Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
UA115989C2 (uk)	2018-01-25	Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EA201000807A1 (ru)	2011-02-28	Производные цефаломаннина, их приготовление, фармацевтические композиции и применение
GB0620619D0 (en)	2006-11-29	Novel compounds
UA99579C2 (ru)	2012-08-27	АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С Tau, ФОСФОРИЛИРОВАННЫМ ПО СЕРИНУ 422 (pS422), ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ТАУПАТИИ
CY1113971T1 (el)	2016-07-27	Νεα παραγωγα αζαδικυκλο [3.2.0] επτ-3-υλ, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CN302314482S (zh)	2013-02-06	气道(兔用)